Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Jay AminEric C Kauffman

Abstract

Purpose: The diagnostic differential for CD117/KIT(+) oncocytic renal tumor biopsies is limited to benign renal oncocytoma versus chromophobe renal cell carcinoma (ChRCC); however, further differentiation is often challenging and requires surgical resection. We investigated clinical variables that might improve preoperative differentiation of CD117(+) renal oncocytoma versus ChRCC to avoid the need for benign tumor resection.Experimental Design: A total of 124 nephrectomy patients from a single institute with 133 renal oncocytoma or ChRCC tumors were studied. Patients from 2003 to 2012 comprised a retrospective cohort to identify clinical/radiographic variables associated with renal oncocytoma versus ChRCC. Prospective validation was performed among consecutive renal oncocytoma/ChRCC tumors resected from 2013 to 2017.Results: Tumor size and younger age were associated with ChRCC, and multifocality with renal oncocytoma; however, the most reliable variable for ChRCC versus renal oncocytoma differentiation was the tumor:cortex peak early-phase enhancement ratio (PEER) using multiphase CT. Among 54 PEER-evaluable tumors in the retrospective cohort [19 CD117(+), 13 CD117(-), 22 CD117-untested], PEER classified each correctly as ren...Continue Reading

References

Mar 1, 1993·Radiology·A J DavidsonC J Davis
Jan 1, 1997·The American Journal of Surgical Pathology·M B AminG M Farrow
Nov 25, 2003·The Journal of Urology·Igor FrankHorst Zincke
Nov 17, 2005·BJU International·Tomas GudbjartssonGudmundur V Einarsson
Dec 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephen RohanYao-Tseng Chen
Nov 13, 2007·The Journal of Urology·Brian R LaneSteven C Campbell
Mar 14, 2008·Urology·Jason RothmanRobert G Uzzo
Jul 8, 2008·Indian Journal of Pathology & Microbiology·Bita GeramizadehMarjan Rahsaz
Oct 14, 2008·European Urology·Mesut Remzi, Michael Marberger
May 8, 2010·Nature Reviews. Urology·Wong-Ho ChowSusan S Devesa
Jan 6, 2011·Archives of Pathology & Laboratory Medicine·Luan D Truong, Steven S Shen
May 29, 2012·European Urology·Alessandro VolpeRobert G Uzzo
May 28, 2013·Virchows Archiv : an International Journal of Pathology·Nicolas PotéMathilde Sibony
Sep 22, 2015·The Journal of Urology·Patrick O RichardAntonio Finelli
Aug 19, 2016·Drug Design, Development and Therapy·Maryam Abbaspour BabaeiFatemeh Ahmadipour
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Aug 3, 2018·Nature Reviews. Urology·Louise Stone
Feb 15, 2019·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Zixiong HuangTao Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.